Core Insights - The COVID-19 pandemic has significantly increased the demand for nucleic acid extraction instruments, with a total procurement of 4,216 units in China in 2022, marking a 46.03% year-on-year growth [1][5] - As the pandemic response transitions to a normalized phase, the market demand is expected to decrease, with projections indicating a drop to 758 units in 2024 and a total procurement amount of 0.94 billion yuan [1][5] - The market is shifting from emergency large-scale procurement to routine purchases focused on equipment updates and regular reserves, leading to a substantial reduction in average prices [1][5] Industry Overview - Nucleic acid extraction is a critical step in molecular biology and genetics, with instruments designed to efficiently extract pure nucleic acids from various samples [2] - The primary extraction methods include magnetic bead and column methods, with magnetic bead technology currently dominating the market [2][3] Market Policies - The Chinese government emphasizes the development of the medical device industry, including nucleic acid extraction instruments, through various policies aimed at regulating market order and ensuring product quality [4][5] Industry Chain - The upstream of the nucleic acid extraction instrument industry includes suppliers of functional materials and precision components, while the midstream consists of manufacturing companies, and the downstream encompasses various application markets such as clinical diagnostics and public health [5] Market Development - The nucleic acid extraction instrument market is experiencing a return to rationality post-pandemic, with procurement amounts and average prices decreasing significantly [1][5] Regional Demand Distribution - The demand for nucleic acid extraction instruments is concentrated in East China, North China, and Southwest China, with these regions contributing 75.13% of the total procurement amount in the first half of 2025 [7] Competitive Landscape - The market concentration is high, with the top six companies (CR6) holding a market share of 52.67% in the first half of 2025, indicating strong competitive advantages among leading firms [6][8] Company Analysis - Xi'an Tianlong Technology Co., Ltd. is a leading player in the nucleic acid extraction market, with a wide range of products and significant certifications, serving numerous medical institutions globally [8] - Shengxiang Biotechnology Co., Ltd. focuses on innovative gene technology and offers a comprehensive range of diagnostic solutions, achieving a revenue of 1.458 billion yuan in 2024 [10] Development Trends - Future trends indicate a move towards full-process automation and integrated technology, enhancing efficiency and reducing contamination risks [11] - Domestic manufacturers are expected to accelerate their penetration into high-end markets and expand globally, leveraging local service advantages [11] - The integration of smart technology and information systems will become a core competitive edge, improving laboratory efficiency and data management [12]